ICON (ICLR) Stock May Be 27% Below Fair Value Despite ESG Progress
ICON stock has delivered a weak share return over the past few years, yet several valuation checks currently point to the shares trading below an estimate of intrinsic value. The market price around US$168.93 contrasts with intrinsic value work that suggests the stock may be pricing in a cautious outlook.
- Over the past 3 years, ICON has fallen about 36.4%, which keeps recent sentiment subdued despite the company remaining a key player in clinical research services.
- Progress on ESG and clinical innovation highlighted in ICON's 2025 ICON Cares Report can support long term cash flow expectations, while any slowdown in clinical trial activity or pressure on customer budgets may weigh on those cash flows.
- On a broad set of checks, including a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples, ICON screens as cheap overall, and the value score of 5 suggests the broader checks lean toward undervaluation.
The issue now is whether ICON's current share price already reflects the risks in its business, or whether the intrinsic value estimate and multiples leave room for a re rating over time.
Expand your watchlist beyond ICON by reviewing our hand picked 51 high quality undervalued stocks, which also screen as cheap on intrinsic value checks.
Does ICON Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here projects how much cash ICON might generate for shareholders and then rolls that back into a single present value per share. ICON produced about $1.02b in free cash flow over the latest twelve months, and the model assumes these cash flows continue growing from this base rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity approach points to an estimated intrinsic value of about $231 per share.
With the recent share price around $168.93, the DCF output suggests ICON screens as around 27.0% undervalued. The 2025 ICON Cares Report, which highlights progress on ESG priorities and AI enabled clinical development work, may help explain why some investors view the cash flow outlook as relatively resilient, even while the market prices in caution.
Based on these cash flow projections relative to today’s share price, ICON stock appears undervalued on this DCF view.
Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 27.0%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.
Is ICON Still Cheap on Sales?
P/S can be a useful cross check for ICON because revenue is a key reference point for contract research businesses that reinvest heavily.
ICON currently trades on a P/S of about 1.6x, which is well below the Life Sciences industry average of 4.5x and also below the peer group level of about 5.4x. A fair P/S ratio tailored to ICON, which factors in its sector, size and risk profile, is estimated at about 3.2x. That is roughly double the present multiple, so the stock trades at a sizeable discount to what this framework suggests could be reasonable.
This gap indicates that, on sales alone, the market is pricing ICON more cautiously than both industry benchmarks and the fair ratio would imply.
On the P/S multiple, ICON stock appears inexpensive compared with both its tailored fair ratio and sector peers.
See what the numbers say about this price — find out in our valuation breakdown.
The ICON Narrative: What Would Justify Today's Price?
Simply Wall St Narratives take the valuation puzzle around ICON and turn it into a set of clear future paths that would make the stock worth materially more or less than today’s price, based on assumptions for growth, margins and earnings. Instead of stopping at a single figure from a ratio or model, they outline the future that number relies on so you can track how ICON's actual progress compares over time on the Community page.
ICON investors are weighing two very different stories around bookings strength on one side and margin and pricing pressure on the other.
Bull case: 9% undervalued
"Strategic investments in AI enabled tools like iSubmit and SmartDraft are set to accelerate trials and enhance data management, which could lead to improved earnings through increased operational efficiency…"
Read the full Bull Case to see why ICON could be undervalued
Bear case: 9% overvalued
"Ongoing elevated cancellation rates persisting at around 2.5% of backlog and including broad based customer portfolio rationalization signal persistent trial volatility and elongation of development timelines…"
Read the full Bear Case to see why ICON could be overvalued
Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!
The Bottom Line
ICON screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on sales-based multiples, which is a rare level of agreement between methods. The crux is whether ICON can translate its clinical research position and ESG and AI work into cash flows that broadly match those intrinsic value assumptions. If revenue growth, margins, and trial activity support that path, the current discount could eventually narrow. If cancellation rates, budget pressure, or weaker bookings remain a drag, the present gap may instead reflect a value trap rather than a clear opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com